SPL-108 mitigates metastasis and chemoresistance in tubo-ovarian carcinoma

SPL-108 mitigates metastasis and chemoresistance in tubo-ovarian carcinoma

Background: Overcoming the heterogeneous mechanisms of metastasis and chemoresistance will improve outcomes for women with tubo-ovarian carcinomas (TOCs). CD44 expression has been shown to be associated with poor prognosis and advanced disease in TOCs. In addition, studies have shown a link between...

Full description

Saved in:

Bibliographic Details
Main Authors:	Olivia D. Lara, Elke Van Oudenhove, Luiza Pereira, Selim Misirlioglu, Douglas A. Levine, Kari E. Hacker
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Translational Oncology
Subjects:	Ovarian cancer Chemoresistance Metastasis Therapeutic approaches Targeted therapies
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324002948
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ascitis as a unique microenvironment of tumors in ovarian cancer: interaction with prognosis and chemoresistance
by: A. B. Villert, et al.
Published: (2019-07-01)

THE IMPACT OF RAD6 EXPRESSION ON CHEMORESISTANT OVARIAN CANCER: A SYSTEMATIC REVIEW
by: Leo Vernadesly, et al.
Published: (2025-01-01)

Restriction of YWHAB-mediated YAP cytoplasmic retention is a novel mechanism underlying stemness maintenance and chemoresistance in ovarian cancer peritoneal metastasis
by: Chang Liu, et al.
Published: (2025-09-01)

Determination of chemoresistance of ovarian cancer cells in vitro
by: K. A. Kuzin, et al.
Published: (2019-12-01)

Novel gene rearrangement leads to altered expression of Hornerin in sensitive and chemoresistant ovarian cancer
by: Ghassan M. Saed, et al.
Published: (2025-11-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)

Nuclear receptor subfamily 1 group D member 2 induces chemoresistance in ovarian cancer by regulating ferroptosis and immune infiltration
by: Linlin Wang, et al.
Published: (2025-07-01)

Clinical cases of management and treatment of women with chemoresistant tuberculosis during pregnancy
by: O. M. Raznatovska, et al.
Published: (2020-07-01)

5-methylcytosine regulated CCNL2 promotes tumorigenesis and cisplatin resistance of ovarian cancer with therapeutic implications
by: Kai Zhang, et al.
Published: (2025-07-01)

Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer
by: Jing Li, et al.
Published: (2024-12-01)

Features and complexity of treatment of <i>BRCA</i>-associated ovarian cancer, chronic disease: literature review
by: T. V. Gorodnova, et al.
Published: (2024-11-01)

The management of tubo-ovarian abscesses associated with appendicitis
by: Lucian Serbanescu, et al.
Published: (2021-10-01)

Warburg effect and lactylation in cancer: mechanisms for chemoresistance
by: Wenjie Zhang, et al.
Published: (2025-04-01)

Tubo-ovarian abscess management in our clinic
by: Necdet Öncü, et al.
Published: (2025-06-01)

DCAF7 Acts as A Scaffold to Recruit USP10 for G3BP1 Deubiquitylation and Facilitates Chemoresistance and Metastasis in Nasopharyngeal Carcinoma
by: Qing‐Jie Li, et al.
Published: (2024-09-01)

The role of TLR-4 in chemoresistance of cancer
by: Yuhua Li, et al.
Published: (2025-05-01)

Chemoresistance factors in non-small cell lung cancer
by: А. I. Shevchenko, et al.
Published: (2016-04-01)

The interplay between COX-2, chemotherapeutic drugs, and chemoresistance in colon cancer
by: Sally M. Shalaby, et al.
Published: (2025-05-01)

Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells
by: Yaman Alghamian, et al.
Published: (2025-03-01)

Clinical case of chemoresistant tuberculosis in the patient with tuberous sclerosis: difficulties of diagnosis, features of the course and treatment.
by: N. S. Kolesnik, et al.
Published: (2019-12-01)

Establishment of a chemoresistant laryngeal cancer cell model to study chemoresistance and chemosensitization responses via transcriptomic analysis and a tumor‐on‐a‐chip platform
by: Christian R. Moya‐Garcia, et al.
Published: (2025-05-01)

WBP1 regulates mitochondrial function and ferroptosis to modulate chemoresistance in colorectal cancer
by: Yang Wang, et al.
Published: (2025-03-01)

Serum Hsa_circ_0023919 is a Predictive Biomarker of Chemoresistance in CRC Treatment
by: Zhang L, et al.
Published: (2024-12-01)

Strain and hyaluronic acid interact to regulate ovarian cancer cell proliferation, migration, and drug resistance
by: Maranda Kramer, et al.
Published: (2024-12-01)

ASSESSMENT OF RECEPTOR CONVERSION ROLE FOR ADVANCED BREAST CANCER ON THE CHEMORESISTANCE OCCURRENCE
by: Oleksii V. Movchan, et al.
Published: (2025-03-01)

Patient‐derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
by: Katharina Bischof, et al.
Published: (2025-01-01)

PNMA1 mediates melphalam chemoresistance in retinoblastoma via promoting DNA repair
by: Longge Sun, et al.
Published: (2025-07-01)

Features of endobronchial pathology among patients with chemoresistant tuberculosis of lungs depending on a case of the previous disease
by: O. M. Raznatovska, et al.
Published: (2017-08-01)

The Role of V-ATPase ATP6V0D1 Subunit in Chemoresistance and Ellipticine-Induced Cytoplasmic Vacuolation in Neuroblastoma Cells
by: M Rychla, et al.
Published: (2025-12-01)

Hsa_circ_0020095 modulates chemoresistance of CRC in a PDO model
by: Xinyu Li, et al.
Published: (2025-05-01)

DNA-methylation eraser TET2 activates WTIP expression to suppress an AKT-dependent chemoresistance of gastric cancer
by: Yan Guo, et al.
Published: (2025-07-01)

Parameters of the glutathione system and thioredoxin in blood plasma and ascites and GSTP1 Ile105Val gene polymorphism as factors of resistance to platinum-containing chemotherapy in ovarian cancer patients
by: D. R. Dolgova, et al.
Published: (2021-01-01)

Tumorspheres as In Vitro Model for Identifying Predictive Chemoresistance and Tumor Aggressiveness Biomarkers in Breast and Colorectal Cancer
by: Toni Martinez-Bernabe, et al.
Published: (2024-09-01)

Hyptolide induces ER stress-mediated cell death and enhances GSK3β-regulated cisplatin chemosensitivity in ovarian cancer
by: Yusi Luluk Rahmania, et al.
Published: (2025-06-01)

Efficiency of postoperated microwave therapy of the patients with inflammated tubo-ovarian tumors
by: I. D. Evtushenko, et al.
Published: (2002-12-01)

An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
by: REN Jiaqiang, WU Shuai, SU Tong, LI Jie, HAN Liang, WU Zheng
Published: (2024-12-01)

Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies
by: John Kaszycki, et al.
Published: (2025-07-01)

Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance
by: Isaac Micallef, et al.
Published: (2024-12-01)

Glycosylated Delphinidins Decrease Chemoresistance to Temozolomide by Regulating NF-κB/MGMT Signaling in Glioblastoma
by: Diego Carrillo-Beltrán, et al.
Published: (2025-01-01)

Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling in the ES-2 Ovarian Carcinoma Cell Line, Influencing Cell Proliferation, Quiescence, and Chemoresistance in a Cell-of-Origin-Specific Manner
by: Isabel Lemos, et al.
Published: (2025-04-01)